Cleveland Stem-Cell Therapy Start-Up; Arteriocyte, Inc. Receives State Research Support; Third Frontier Funding to Advance Development of Adult Stem Cell-Based Therapies.CLEVELAND -- Arteriocyte Inc., a Cleveland-based, biotechnology startup currently conducting a Phase I clinical trial Noun 1. phase I clinical trial - a clinical trial on a few persons to determine the safety of a new drug or invasive medical device; for drugs, dosage or toxicity limits should be obtained phase I for an adult, bone-marrow-derived stem cell therapy stem cell therapy Cell therapy Molecular medicine A technology in which a person's own cells–eg, neuronal stem cells are triggered to revert to their primitive embryonic form, then redifferentiate into mature cells of various organs designed to generate new blood vessels in ischemic Ischemic An inadequate supply of blood to a part of the body, caused by partial or total blockage of an artery. Mentioned in: Antiangiogenic Therapy, Subarachnoid Hemorrhage, Ventricular Fibrillation ischemic tissues, has received a $600,000 grant from the State of Ohio to further the development of its technology. The funding, received as part of an $8 million Third Frontier award to Cleveland's Center for Stem Cell and Regenerative Medicine (CSCRM CSCRM Capacitor Start Capacitor Run Motor ), will help fuel the company's collaboration with other CSCRM researchers. The CSCRM is a multi-institutional initiative that includes Case Western Reserve University, University Hospitals of Cleveland University Hospitals is a major not-for-profit medical center in Cleveland, Ohio, United States. With 150 locations throughout northeast Ohio, it encompasses a network of hospitals, outpatient centers and primary care physicians. , the Cleveland Clinic Foundation, and the Ohio State University Ohio State University, main campus at Columbus; land-grant and state supported; coeducational; chartered 1870, opened 1873 as Ohio Agricultural and Mechanical College, renamed 1878. There are also campuses at Lima, Mansfield, Marion, and Newark. . "The Third Frontier funding comes at an important time for Arteriocyte," said Donald Brown, the company's Chief Executive Officer. "We recently passed the midpoint of enrollment for our Phase I clinical trial in patients suffering from coronary artery ischemia, and are projecting complete enrollment by the end of June. This award from the Third Frontier commission is further validation of the progress Arteriocyte has made in developing its cellular therapy, and will help accelerate that progress." "Arteriocyte is a clear example of how the Third Frontier Commission's support of the CSCRM and other biomedical research and commercialization efforts in the state is helping to develop technologies and innovations that can benefit Ohio residents," said Lt. Governor Bruce Johnson, who also serves as Director of the Ohio Department of Development. About Arteriocyte Arteriocyte is a clinical stage research and development biotechnology company based in Cleveland, Ohio that is developing proprietary, non-embryonic stem cell-based therapies targeted for the treatment of ischemia in patients suffering from coronary artery disease coronary artery disease, condition that results when the coronary arteries are narrowed or occluded, most commonly by atherosclerotic deposits of fibrous and fatty tissue. , peripheral vascular disease Peripheral Vascular Disease Definition Peripheral vascular disease is a narrowing of blood vessels that restricts blood flow. It mostly occurs in the legs, but is sometimes seen in the arms. , stroke, and renal ischemia. The Company was founded in January of 2004 and is based upon more than four years of NIH-sponsored research utilizing stem cells to stimulate angiogenesis (new vessel growth)., Arteriocyte's ultimate goal is to develop umbilical cord blood umbilical cord blood Transplantation A source of primitive and stem cells that can be used to reconstitute BM destroyed by aplastic anemia or by RT or chemotherapy for CA, lymphoproliferative malignancies. See Bone marrow transplantation, Stem cell therapy. - a rich source of stem cells - as the basis for the company's future cellular medicines. About the Third Frontier Project Governor Taft unveiled The Third Frontier Project in February 2002. This project is the state's largest-ever commitment to expanding Ohio's high-tech research capabilities and promoting innovation and company formation that will create high-paying jobs for generations to come. The 10-year, $1.6 billion initiative is designed to build world-class research capacity, support early stage capital formation and the development of new products, and finance advanced manufacturing technologies to help existing industries become more productive. Through the Third Frontier Project, additional federal and private sector support can boost the total investment to more than $6 billion. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion